FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burd	len								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Kelly Lisa				<u>V</u>	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								eck all application	able)	oorting Person(s) to Issuer 10% Owner title Other (specify		ner		
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 02/04/2010								X Officer (give title Officer (specify below) SVP, Human Resources					
130 WAVERLY STREET					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02139														X Form fil	Form filed by More than One Reporting				
(City)	(5	State)	(Zip)																
		Tal	ble I - Noi	n-Deri	vativ	/e Se	curities	Acq	uired,	Dis	posed of	, or Ben	eficial	y Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				saction /Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr.		ies Acquired (A) o Of (D) (Instr. 3, 4		5. Amour Securitie Beneficia Owned F Reported	s Illy ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)	Price	Transacti (Instr. 3 a	on(s)					
Common Stock 02/04/)4/20	/2010		A		10,166(1	1) A	\$0.0	1 34,	563	Ι)			
Common Stock												1,0)98]	I 4	101(k)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, T	Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title an of Securit Underlyin Derivative (Instr. 3 an	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio	ly C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)		Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	/11(3)			
Stock Option	\$39.05	02/04/2010			A		76,250 ⁽²⁾		05/04/20	10	02/03/2020	Common Stock	76,250	\$0	76,250		D		

Explanation of Responses:

1. Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012.

2. Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years.

Remarks:

Kenneth S. Boger, Attorney-In-

Fact

** Signature of Reporting Person

02/08/2010

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.